Last Update Time:
13-Mar-2025 16:00:00
ISIN:
INE406M01024
Sector:
Healthcare
Symbol:
ERIS
Eris Lifesciences Limited
₹1,247.20
₹-18.15
(-1.43%)
▼
Prev. Close
₹1,265.35
Open
₹1,257.85
Close
₹1,254.75
Range
₹1,184.84 - ₹1,309.56
High
₹1,274.90
Low
₹1,241.30
Ind. Close
₹0.00
VWAP
₹1,253.75
The current stock price of Eris Lifesciences Limited is ₹1,247.20, with a target price range between ₹1,184.84 and ₹1,309.56. The stock has experienced a price change of ₹-18.15 (-1.43%), reflecting recent market volatility.
Today's opening price was ₹1,257.85, while the previous close stood at ₹1,265.35.
The market trend suggests a potential downtrend, with investors exercising caution due to recent declines. Analysts recommend closely monitoring support levels.
For real-time stock market updates, live share prices, and stock analysis, stay tuned. Understanding key stock metrics like VWAP, high-low range, and market momentum can help traders make informed investment decisions.
Eris Lifesciences Limited Price Chart
Eris Lifesciences Limited Pre Open Market Overview: 13-Mar-2025
Key Metrics:
- IEP (Indicative Equilibrium Price): 1257.85
- Previous Close Price: 1265.35
- Change: -7.50%
- Total Traded Volume: 36
- Total Buy Quantity: 319
- Total Sell Quantity: 852
| Price | Buy Qty | Sell Qty |
|---|---|---|
| 1,235.00 | 100.00 | 0.00 |
| 1,246.45 | 3.00 | 0.00 |
| 1,251.00 | 10.00 | 0.00 |
| 1,255.00 | 20.00 | 0.00 |
| 1,257.85 | 8.00 | 0.00 |
| 1,265.35 | 0.00 | 6.00 |
| 1,274.90 | 0.00 | 100.00 |
| 1,275.00 | 0.00 | 20.00 |
| 1,276.65 | 0.00 | 26.00 |
| 1,277.00 | 0.00 | 4.00 |
ATO Data:
- Buy Quantity (ATO): 0
- Sell Quantity (ATO): 0
Order Book
| Bid | Qty | Ask | Qty |
|---|---|---|---|
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
| 0.00 | 0 | 0.00 | 0 |
Total Buy Quantity: 319
Total Sell Quantity: 852
Shareholding Patterns of Eris Lifesciences Limited
Key Trade Statistics of Eris Lifesciences Limited
| Trade Information | Details |
|---|---|
| Traded Volume (Lakhs) | 0.46 |
| Traded Value (₹ Cr.) | 5.74 |
| Total Market Cap (₹ Cr.) | 16,982.20 |
| Free Float Market Cap (₹ Cr.) | 6,458.96 |
| Impact cost | 0.09 |
| Quantity Traded | 45,777.00 |
| Deliverable Quantity | 24,378.00 |
| % of Quantity to Traded | 53.25 |
| Security VaR | 12.81 |
| Index VaR | N/A |
| VaR Margin | 12.81 |
| Extreme Loss Rate | 3.5 |
| Adhoc Margin | N/A |
| Applicable Margin Rate | 16.31 |
| Face Value | 1 |
Key Price Statistics of Eris Lifesciences Limited
The 52-week high for Eris Lifesciences Limited was ₹1,593.90, recorded on 11-Dec-2024. On the other hand, the 52-week low stands at ₹809.15, with the lowest value recorded on 13-Mar-2024.
The upper band for trading is ₹1,518.40, and the lower band is ₹1,012.30. The price band is 20%.
The stock's daily volatility stands at 2.01, while the annualized volatility is 38.40. The tick size for trading is ₹0.05.
| Price Information | Details |
|---|---|
| 52 Week High (11-Dec-2024) | 1,593.90 |
| 52 Week Low (13-Mar-2024) | 809.15 |
| Upper Band | 1,518.40 |
| Lower Band | 1,012.30 |
| Price Band (%) | 20 |
| Daily Volatility | 2.01 |
| Annualised Volatility | 38.40 |
| Tick Size | 0.05 |
Key Securities Statistics of Eris Lifesciences Limited
| Securities Information | Details |
|---|---|
| Status | Listed |
| Trading Status | Active |
| Date of Listing | 29-Jun-2017 |
| Adjusted P/E | 48.49 |
| Symbol P/E | 48.49 |
| Index | NIFTY 500 |
| Macro-Economic Sector | Healthcare |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Basic Industry | Pharmaceuticals |
Security Status of Eris Lifesciences Limited
| Title | Details |
|---|---|
| Board Status | Main |
| Trading Segment | Normal Market |
| Session No. | - |
| Class of Shares | Equity |
| SDD Compliance | - |
| Name of Compliance Officer | - |
Announcements of Eris Lifesciences Limited
| Subject | Date |
|---|---|
| Analysts/Institutional Investor Meet/Con. Call Updates | 07-Mar-2025 |
| Updates | 06-Mar-2025 |
| Alteration Of Capital and Fund Raising-XBRL | 06-Mar-2025 |
| ESOP/ESOS/ESPS | 06-Mar-2025 |
| Updates | 27-Feb-2025 |
| Analysts/Institutional Investor Meet/Con. Call Updates | 24-Feb-2025 |
| Redemption | 21-Feb-2025 |
| Agreements | 21-Feb-2025 |
Corporate Actions of Eris Lifesciences Limited
| Face Value | Purpose | Ex-Date |
|---|---|---|
| 1 | Interim Dividend - Rs 7.35 Per Share | 13-Feb-2025 |
| 1 | Annual General Meeting | 17-Sep-2024 |
| 1 | Annual General Meeting | 15-Sep-2023 |
| 1 | Annual General Meeting | 23-Aug-2022 |
| 1 | Interim Dividend- Rs 7.35 Per Share | 11-Aug-2022 |
| 1 | Annual General Meeting | 23-Aug-2021 |
| 1 | Interim Dividend - Rs 6.01 Per Share | 05-Aug-2021 |
| 1 | Annual General Meeting | 18-Sep-2020 |
| 1 | Interim Dividend - Rs 5.50 Per Share | 13-Aug-2020 |
| 1 | Interim Dividend - Rs 2.87 Per Share | 19-Mar-2020 |
| 1 | Annual General Meeting | 18-Sep-2019 |
| 1 | Buyback | 12-Jul-2019 |
| 1 | Annual General Meeting | 19-Sep-2018 |
| 1 | Annual General Meeting | 20-Sep-2017 |
Board Meetings of Eris Lifesciences Limited
Financial Results of Eris Lifesciences Limited
Company Directory of Eris Lifesciences Limited
| Web Address | Office | Address | City |
|---|---|---|---|
| www.eris.co.in | Head Office/ Corporate Office | Shivarth Ambit, Plot No. 142/2, Ramdas Road, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad - 380054 | AHMEDABAD |
| www.eris.co.in | Registered Office | Shivarth Ambit, Plot No 142/2, Ramdas Road Off SBR Near Swati Bungalows, Bodakdev, Ahmedabad | AHMEDABAD |
| www.eris.co.in | Transfer Agent | Link Intime India Private Limited C-101, 1st Floor, 247 Park L.B.S. Marg, Vikhroli (West) | MUMBAI |
Insider Trading of Eris Lifesciences Limited
| Reg. Clause | Acq./Disp. | Sec. Value | Txn Type |
|---|---|---|---|
| 7(2) | Sabyasachi Sharma | 1591492 | Sell |
| 7(2) | Amit Indubhushan Bakshi | 7226835 | Buy |
| 7(2) | Amit Indubhushan Bakshi | 127890000 | Buy |
| 7(2) | Amit Indubhushan Bakshi | 262721706 | Buy |
| 7(2) | Amit Indubhushan Bakshi | 109015828 | Buy |
| 7(2) | Vijaya Sampath | 2366144 | Sell |
| 7(2) | Sabyasachi Sharma | 2250689 | Buy |
| 7(2) | Chetan Doshi | 2229490 | Buy |
| 7(2) | Chetan Doshi | 1417800 | Sell |
| 7(2) | Sabyasachi Sharma | 2139800 | Sell |
| 7(2) | Chetan Doshi | 2029680 | Buy |
| 7(2) | Chetan Doshi | 798950 | Sell |
| 7(2) | Vijay Joshi | 2499664 | Buy |
| 7(2) | Chetan Doshi | 3608320 | Buy |
| 7(2) | Himanshu Jayantbhai Shah | 8399362 | Sell |
| 7(2) | Himanshu Jayantbhai Shah | 1741557 | Sell |
| 7(2) | Chetan Doshi | 1127600 | Buy |
| 7(2) | Vijay Joshi | 2499663 | Buy |
| 7(2) | Sachin Shah | 4499124 | Buy |
| 7(2) | CHETAN DOSHI | 678258 | Sell |
Annual Reports of Eris Lifesciences Limited
Investor Complaints of Eris Lifesciences Limited
Event Calendar of Eris Lifesciences Limited
| Purpose | Details |
|---|---|
| Results | To, inter alia, consider and approve the standalone and consolidated unaudited financial results of the Company for the quarter /Three months ended June 30, 2017. |
| Results | To, inter alia, consider and approve the standalone and consolidated unaudited financial results of the Company for the quarter / Half year ended September 30, 2017. |
| Results | To, inter alia, consider and approve the standalone and consolidated unaudited financial results of the Company for the quarter ended December 31, 2017.ￂﾠ |
| Financial Results | To consider and approve the standalone and consolidated audited financial results of the Company for the quarter and year ended March 31, 2018 |
| Financial Results | Newspaper Advertisement - Notice of Board Meeting |
| Financial Results/Other business matters | To consider and approve the financial results for the period ended Jun 30, 2018 and other business matters |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2018 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2018 |
| Financial Results | Newspaper Advertisement - Notice of Board Meeting |
| Financial Results | To consider and approve the financial results for the quarter and year March 31, 2019 |
| Buyback | To consider buyback for equity shares |
| Financial Results | Newspaper Advertisement - Notice of Board Meeting |
| Financial Results | To consider and approve the financial results for the period ended June 30, 2019 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2019 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2019 |
| Dividend | To considerￂﾠ interim dividendￂﾠ |
| Financial Results | To consider and approve the financial results for the period ended March 31, 2020 |
| Financial Results | To consider and approve the financial results for the period ended March 31, 2020 |
| Financial Results/Dividend | To consider and approve the financial results for the period ended Jun 30, 2020 and dividend |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2020 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2020 |
| Financial Results/Other business matters | To consider and approve the financial results for the period ended March 31, 2021 and other business matters |
| Dividend | To consider interim dividend and other subject matters |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2021 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2021 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2021 |
| Financial results | Eris Lifesciences Limited has informed the Exchange about Board Meeting to be held on 03-May-2022 to consider financial statements for the period ended March 2022 |
| Financial results | Eris Lifesciences Limited has informed the Exchange about Board Meeting to be held on 05-Aug-2022 to consider financial results for the period ended June 2022 |
| Dividend | Eris Lifesciences Limited has informed the Exchange about Board Meeting to be held on 05-Aug-2022 to consider interim Dividend |
| Financial results | Eris Lifesciences Limited has informed the Exchange about the Board Meeting to be held on 20-Oct-2022 to consider and approve standalone and consolidated financial results for the period ended September 2022 |
| Financial Results | Board Meeting Intimation for Consideration and Approval of the financial results for the period ended December 31, 2022 |
| Financial Results | To consider and approve the standalone and consolidated audited financial results of the Company for the quarter and year ended 31st March, 2023. |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2023 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2023 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2023 |
| Financial Results | To consider and approve the financial results for the period ended March 31, 2024 |
| Fund Raising | To consider Fund Raising |
| Financial Results | To consider and approve the financial results for the period ended Jun 30, 2024 |
| Financial Results | To consider and approve the financial results for the period ended September 30, 2024 |
| Financial Results | To consider and approve the financial results for the period ended December 31, 2024 |
| Dividend | To consider interim dividend |
Share Transfers of Eris Lifesciences Limited
Voting Results of Eris Lifesciences Limited
| Date of Mtg. | Mtg. Type | Resolution |
|---|---|---|
| 25-SEP-2024 | AGM | To receive, consider and adopt the Audited Standalone Financial Statements including Audited Consolidated Financial Statements of the Company for the Financial Year ended March 31, 2024, and the reports of the Board of Directors and the Auditors thereon; |
| 25-SEP-2024 | AGM | To consider and approve Alteration in the Articles of Association of the Company |
| 25-SEP-2024 | AGM | To ratify the remuneration of Cost Auditors for the Financial Year ending March 31, 2025. |
| 25-SEP-2024 | AGM | To appoint a Director in place of Mr. Inderjeet Singh Negi (DIN: 01255388) who retires by rotation and, being eligible, offers himself for re-appointment; |
| 25-SEP-2023 | AGM | To receive, consider and adopt the Audited Standalone Financial Statements including Audited Consolidated FinancialnStatements of the Company for the Financial Year ended on March 31, 2023 and the reports of the Board of Directors andnthe Auditors thereon |
| 25-SEP-2023 | AGM | Approval to advance loan(s), to give any guarantee(s) and/or to provide any security(ies) under Section 185 of the CompaniesnAct, 2013 and in this regard, to pass with or without modification(s), the following resolution as a Special Resolution |
| 25-SEP-2023 | AGM | To ratify the remuneration of Cost Auditors for the Financial Year ending March 31, 2024 and in this regard, to pass with ornwithout modification(s) the following resolution as an Ordinary Resolutionn |
| 25-SEP-2023 | AGM | To appoint a Director in place of Mr. Krishnakumar Vaidyanathan (DIN: 08976508) who retires by rotation and, being eligible,noffers himself for re-appointment. |
| 01-SEP-2022 | AGM | To receive, consider and adopt the Audited Standalone Financial Statements including Audited Consolidated Financial Statements of the Company for the Financial Year ended on March 31, 2022 and the reports of the Board of Directors and Auditors thereon. |
| 01-SEP-2022 | AGM | To appoint Mr. Sujesh Vasudevan as an Independent Director of the Company |
| 01-SEP-2022 | AGM | To re-appoint Mr. Prashant Gupta as an Independent Director of the Company; |
| 01-SEP-2022 | AGM | To ratify the remuneration of Cost Auditors for the Financial Year ending March 31, 2023 |
| 01-SEP-2022 | AGM | To appoint a Director in place of Mr. Amit Bakshi, (DIN: 01250925) who retires by rotation and, being eligible, offers himself for re-appointment. |
| 01-SEP-2021 | AGM | To receive, consider and adopt the Audited Standalone Financial Statements including Audited Consolidated Financial Statements of the Company for the financial year ended March 31, 2021 and the reports of Board of Directors and Auditors thereon. |
| 01-SEP-2021 | AGM | To re-appoint Mrs. Vijaya Sampath as an Independent Director of the Company. |
| 01-SEP-2021 | AGM | To appoint Ms. Kalpana Unadkat as an Independent Director of the Company. |
| 01-SEP-2021 | AGM | To appoint Mr. Rajeev Dalal as an Independent Director of the Company. |
| 01-SEP-2021 | AGM | To ratify the remuneration of Cost Auditors for the Financial Year ending March 31, 2022. |
| 01-SEP-2021 | AGM | To re-appoint M/s. Deloitte Haskins & Sells LLP, Chartered Accountants as the Statutory Auditors of the Company for four years, i.e., FY 2021-22 to FY 2024-25. |
| 01-SEP-2021 | AGM | To appoint a director in place of Mr. Kaushal Shah (DIN: 01229038) who retires by rotation and being eligible, offers himself for reappointment. |
FAQs on Eris Lifesciences Limited
Disclaimer: The information provided here is for informational purposes only and should not be considered financial advice. Please do your own research and consult with a financial professional before making any investment decisions.